CRF 12- ACTIVE TB – FINAL EVALUATION FORM

A1.Participant's ID number C C C - C C C C

TF0. Research staff completing the form

TO BE COMPLETED AT END OF TB TREATMENT

ACTIVE TB FINAL EVALUATION TF1. Date C C C C C C C C D D M M M Y Y Y TF1.1 Was study participant diagnosed with (or died of) active TB? C No (go to question TF30) C Yes TF2. If yes to TF2: Is the study participant being treated (here or elsewhere) for active TB? C No C Yes TF3. If yes to TF2: Was study participant diagnosed with active TB and died? c No c Yes INITIAL INVESTIGATIONS TF4. Chest x-ray at the time of diagnosis? c No c Yes TF5. If yes, date C C C C C C C C (Send copy of film to the coordinating center by 2R2 website) TF6. Other radiological tests? c No c Yes TF7. If yes, date C C C C C C C C TF8. If yes, name of the test _____ (Send copy of film to the coordinating center by 2R2 website) TF9. Microbiology specimen sent? c No c Yes TF10. If yes, date 1st specimen was sent C C C C C C C C D D M M M Y Y Y TF11. If yes, number of spontaneous sputum samples sent C TF12. If yes, number of induced sputum samples sent TF13. AFB smear done? c No c Yes TF14. If yes, number done: C TF15. If yes, results: c All contaminated c All Negative c At least one positive TF16. PCR or GeneXpert? c No c Yes TF17. If yes, results: c All contaminated c Negative (DNA not detected) c Positive (DNA detected) c Unknown TF18. Cultures done? c No c Yes TF19. If yes, number done: C

TF20. If yes, results: c All contaminated c All Negative c At least one positive

*Note: If positive culture, specimen must be sent for identification of MTB and drug susceptibility test.

CRF 12- ACTIVE TB - FINAL EVALUATION FORM

A1.Participant's ID number C C C C C C

Δ2	Center		
AZ.	Center		

TF21. MTB identified? c No c Yes			
TF22. If MTB identified, specimen is: C Sensitive to all drugs C Resistant			
TF23. If resistant, to which drugs?			
TF24. Biopsy or Needle aspiration done? c No c Yes			
TF25. If yes, date			
TF26. If yes, provide results (check all that apply):			
c Normal c Non-necrotizing granulomas c Necrotizing granuloma c AFB seen c Other			
TF27. HIV test done (strongly recommended)? c Yes c No c Not necessary (already known HIV+)			
TF28. If yes, date HIV test was performed			
TF29. If yes, results: c Positive c Negative c Unknown			
TF30. Describe the symptoms, the history of the illness and any unusual findings in as much detail as possible. (note: if participant was NOT diagnosed with active TB, provide alternative diagnosis that was made)			
DIAGNOSIS & TREATMENT			
TF31. Site of TB c Pulmonary c Other TF32. If other, specify			
TF33-36. Method of diagnosis (choose all that apply) c Radiological c Microbiological c Pathology			
TF37. Is the date treatment started confirmed to be the one reported in CRF11? c Yes c No c Date was not known			
TF38. If No, provide new start date: C C C C C C C C C C			
TF39. Did the treatment change since what reported in CRF11? c Yes c No c Treatment was not known TF40. If Yes, provide new treatment			

CRF 12- ACTIVE TB - FINAL EVALUATION FORM

A1.Participant's ID number C C C C C C

A2. Center _____

RESPONSE TO TREATMENT
TF41. Symptoms resolved? C No C Yes
TF42. Tolerability of the therapy
TF43. Estimated Adherence
TF44. Completed therapy c No c Yes
TF45. If yes, date completed C C C C C C C C C C C C C
TF46. Treatment outcome: c Died c Failed c Drop-out c Completed c Cured c Other
TF47. If other, specify
TF48. Sputum for AFB and culture during treatment? c None c Yes
TF49. AFB smear done? c No c Yes
TF50. If yes, number done C
TF51. If yes, results: c All negative c At least one positive c All contaminated
TF52. Cultures done? c No c Yes
TF53. If yes, number done $ {f C} $
TF54. If yes, results: c All negative c At least one positive c All contaminated
TF55. If positive, date of the last positive $\begin{array}{cccccccccccccccccccccccccccccccccccc$
TF56. Chest x-ray or other imaging at the end of treatment for active TB (within 1 month of the end of treatment)
c No c Yes TF57. If yes, date done C C C C C C C C C
(Send film to the coordinating center by 2R2 website)
TF58. Comments